Guosen: The small nucleic acid CXO industry's prosperity continues to rise, entering the stage of clinical realization and commercialization acceleration.

Guosen released a research report stating that small nucleic acid CXO, as the core support of the small nucleic acid drug industry, benefits from technological breakthroughs and commercial acceleration, and the industry's prosperity continues to rise. The small nucleic acid CXO industry has entered the fast lane of development, forming a CRDMO full-chain service system of "R&D services - pilot scale-up - commercial production" simultaneously. The report focuses on two types of CXO companies that are strategically positioning themselves in the field of small nucleic acids: CRO companies with core technologies such as chemical modification, delivery technology, and coupling technology, and rich experience in small nucleic acid projects; and forward-looking CDMO companies with leading production capabilities. The report states that small nucleic acid drugs are entering a period of vigorous development worldwide, transitioning from the technical verification stage to clinical realization and commercial acceleration stage. On a global scale, from 2019 to 2023, the global market size of small nucleic acids is expected to grow from $2.7 billion to $4.6 billion (CAGR of 14.25%); the market size is projected to rise to $45.7 billion by 2033 (with a CAGR as high as 26.08%). There are currently 23 approved drugs on the global market, covering various technologies such as siRNA, ASO, aptamers, etc. Although no products have been launched domestically yet, China has the second-highest number of research pipelines after the United States, covering multiple therapeutic areas such as hyperlipidemia, hypertension, hepatitis B, kidney disease, muscular diseases, obesity, etc. There have been significant outbound transactions, such as Beigene Pharmaceutical and Novartis's collaboration worth over $9 billion, RiboBio and Boehringer Ingelheim's $2 billion platform authorization, and traditional pharmaceutical companies like China Biologic acquiring quickly to position themselves in the industry, demonstrating a positive development trend.